Insulin initiation and intensification in patients with T2DM for the primary care physician

被引:15
|
作者
Unger, Jeff [1 ]
机构
[1] Catalina Res Inst, 14726 Ramona Ave,Suite 110, Chino, CA 91710 USA
关键词
diabetes; basal; bolus; regimens; insulin analogs; structured glucose testing;
D O I
10.2147/DMSO.S14653
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes mellitus (T2DM) is characterized by both insulin resistance and inadequate insulin secretion. All patients with the disease require treatment to achieve and maintain the target glycosylated hemoglobin (A1C) level of 6.5%- 7%. Pharmacological - management of T2DM typically begins with the introduction of oral medications, and the majority of patients require exogenous insulin therapy at some point in time. Primary care physicians play an essential role in the management of T2DM since they often initiate insulin therapy and intensify regimens over time as needed. Although insulin therapy is prescribed on an individualized basis, treatment usually begins with basal insulin added to a background therapy of oral agents. Prandial insulin injections may be added if glycemic targets are not achieved. Treatments may be intensified over time using patient-friendly titration algorithms. The goal of insulin intensification within the primary care setting is to minimize patients' exposure to chronic hyperglycemia and weight gain, and reduce patients' risk of hypoglycemia, while achieving individualized fasting, postprandial, and A1C targets. Simplified treatment protocols and insulin delivery devices allow physicians to become efficient prescribers of insulin intensification within the primary care arena.
引用
收藏
页码:253 / 261
页数:9
相关论文
共 50 条
  • [21] Insulin plus metformin for T2DM—are there benefits?
    Clifford J. Bailey
    Nature Reviews Endocrinology, 2012, 8 : 449 - 450
  • [22] Treating T2DM with Early Insulin Therapy
    Agarwal, Amit
    Norton, Pamela
    McNamara, John
    GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2010, 30 (09): : 49 - +
  • [23] A prospective cohort study for the prevalence and screening policy of NAFLD in patients with T2DM in primary care
    Forlano, Roberta
    Mullish, Benjamin H.
    Yee, Michael
    Goldin, Robert D.
    Thursz, Mark
    Manousou, Pinelopi
    JOURNAL OF HEPATOLOGY, 2021, 75 : S558 - S559
  • [24] Impact of Time to Basal Insulin Initiation on Glycemic Control and Health Care Costs in T2DM Patients: An Analysis of US Commercial Claims Data
    Blonde, Lawrence
    Lew, Elisheva
    Raccah, Denis
    Meyers, Juliana
    Ajmera, Mayank
    Davis, Keith
    Bertolini, Monica
    Guerci, Bruno
    DIABETES, 2017, 66 : A357 - A357
  • [25] Dapagliflozin Pilot Study in Insulin-Resistant T2DM Patients
    Wilding, John P. H.
    Norwood, Paul
    T'joen, Caroline
    Bastien, Arnaud
    List, James F.
    Fiedorek, Fred T.
    DIABETES, 2009, 58 : A129 - A129
  • [26] Clinical inertia in patients with T2DM requiring insulin in family practice
    Harris, Stewart B.
    Kapor, Jovana
    Lank, Cynthia N.
    Willan, Andrew R.
    Houston, Tricia
    CANADIAN FAMILY PHYSICIAN, 2010, 56 (12) : E418 - E424
  • [27] Acanthosis nigricans suggesting insulin resistance and secretion in T2DM patients
    Sharma, L.
    Mathur, S. K.
    Khilnani, G.
    Mathur, M.
    Mathur, P.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 226 - 226
  • [28] Unmet Needs and Treatment Patterns of T2DM Patients with Basal Insulin
    Dalal, Mehul
    Grabner, Michael
    Gidaya, Nicole
    Bieszk, Nella
    Digenio, Andres
    DIABETES, 2014, 63 : A232 - A232
  • [29] Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM)
    Fonseca, Vivian
    Dejager, Sylvie
    Albrecht, Diego
    Shirt, Lynda
    Schweizer, Anja
    DIABETES, 2006, 55 : A111 - A111
  • [30] FDA approves Fiasp insulin for T1DM and T2DM
    不详
    NURSE PRACTITIONER, 2018, 43 (01): : 56 - 56